Document is current

Article History

Received: 15 March 2023

Accepted: 10 September 2024

First Online: 16 October 2024

Declarations

:

: AS received lecture fees from Terumo and Abbott. SM received lecture fees from Novo Nordisc, Eli Lilly and Boehringer Ingelheim. AT received lecture fees from Eli Lilly, Abbott, Sanofi and Terumo. AK received lecture fees from Eli Lilly. JM received lecture fees from Terumo. YH received lecture fees from Eli Lilly, Sanofi, Abbott, Terumo and Sumitomo Pharma, and research expenses and grants from Sumitomo Pharma. MT received lecture fees from Abbott, Eli Lilly, Sumitomo Pharma, Novo Nordisc and Boehringer Ingelheim and subsides or donations from Cocokara fine Healthcare Inc, LifeScan Japan, Roche DC Japan, SUPER LIGHT WATER CO., LTD. TT received lecture fees from Eli Lilly, and research expenses and grants from AstraZeneca.

: This study conformed to the standards of the Declaration of Helsinki.

: This study is registered in the Japan Registry of Clinical Trials (jRCT1052180075). The study protocol received Certified Review Board (CRB) approval from National Hospital Organization Osaka National Hospital (N2018002, originally approved on February 14, 2019, Version 0.7; the latest revision was approved on May 26, 2020, Version 1.6).

: Informed consent or substitute for it was obtained from all the patients for being included in the study.

: Not applicable.